Education
About Us
Working with TipRanks
Follow Us
Anika Therapeutics (ANIK)
NASDAQ:ANIK
Total Valuation
Anika Therapeutics has a market cap or net worth of $192.79M. The enterprise value is $329.94M.
Market Cap$192.79M
Enterprise Value$329.94M
Share Statistics
Anika Therapeutics has 14.18M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding14.18M
Owened by Insiders3.53%
Owened by Instutions39.90%
Financial Efficiency
Anika Therapeutics’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -8.98%.
Return on Equity (ROE)-36.62%
Return on Assets (ROA)-27.81%
Return on Invested Capital (ROIC)-8.98%
Return on Capital Employed (ROCE)-2.84%
Revenue Per Employee$416,343.75
Profits Per Employee-$195,781.25
Employee Count288
Asset Turnover0.59
Inventory Turnover1.84
Valuation Ratios
The current PE Ratio of Anika Therapeutics is -4.30. Anika Therapeutics’s PEG ratio is 0.13.
PE Ratio-4.30
PS Ratio2.02
PB Ratio1.57
Price to Fair Value1.57
Price to FCF-103.95
Price to Operating Cash Flow44.85
PEG Ratio0.13
Income Statement
In the last 12 months, Anika Therapeutics had revenue of $119.91M and earned -$56.38M in profits. Earnings per share was -$3.84.
Revenue$119.91M
Gross Profit$76.00M
Operating Income-$5.10M
Pretax Income-$2.76M
Net Income-$56.38M
EBITDA1.45M
Earnings Per Share (EPS)-3.84
Cash Flow
In the last 12 months, operating cash flow was $5.40M and capital expenditures -$7.73M, giving a free cash flow of -$2.33M billion.
Operating Cash Flow$5.40M
Free Cash Flow-$2.33M
Free Cash Flow per Share-$0.16
Dividends & Yields
Anika Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-0.96%
Earnings Yield-23.27%
Stock Price Statistics
Beta0.74
52-Week Price Change-46.11%
50-Day Moving Average16.34
200-Day Moving Average20.62
Relative Strength Index (RSI)34.67
Average Volume (3m)87.89K
Important Dates
Anika Therapeutics upcoming earnings date is May 7, 2025, After Close.
Last Earnings DateMar 12, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Anika Therapeutics as a current ratio of 4.88, with Debt / Equity ratio of 0.17
Current Ratio4.88
Quick Ratio3.85
Debt to Market Cap0.10
Net Debt to EBITDA5.82
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Anika Therapeutics has paid $6.06M in taxes.
Income Tax$6.06M
Effective Tax Rate-219.39%
Enterprise Valuation
Anika Therapeutics EV to EBITDA ratio is -41.68, with an EV/FCF ratio of -91.21.
EV to Sales1.77
EV to EBITDA-41.68
EV to Free Cash Flow-91.21
EV to Operating Cash Flow39.35
Balance Sheet
Anika Therapeutics has $55.63M in cash and marketable securities with $25.93M in debt, giving a net cash position of -$29.70M billion.
Cash & Marketable Securities$55.63M
Total Debt$25.93M
Net Cash-$29.70M
Net Cash Per Share-$2.09
Tangible Book Value Per Share$9.81
Margins
Gross margin is 63.38%, with operating margin of -4.25%, and net profit margin of -47.02%.
Gross Margin63.38%
Operating Margin-4.25%
Pretax Margin-2.31%
Net Profit Margin-47.02%
EBITDA Margin-4.25%
EBIT Margin-4.25%
Analyst Forecast
The average price target for Anika Therapeutics is $24.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$24.00
Price Target Upside75.95%
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-8.92%
EPS Growth Forecast31.98%